Depletion of endogenous kallistatin exacerbates renal and cardiovascular oxidative stress, inflammation, and organ remodeling

American Journal of Physiology - Renal Physiology

Volumn 303, Issue 8, 2012, Pages

  Chao, Julie ^a   Liu, Yuying ^a   Bledsoe, Grant ^b   Hagiwara, Makato ^a   Shen, Bo ^a   Chao, Lee ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b CHARLESTON SOUTHERN UNIVERSITY   (United States)

Author keywords

Fibrosis; Heart; Hypertrophy; Kidney

Indexed keywords

COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CREATININE; INTERCELLULAR ADHESION MOLECULE 1; KALLISTATIN ANTIBODY; NITRIC OXIDE; NITROGEN; PLASMA PROTEIN; PROTEIN ANTIBODY; PROTEIN KALLISTATIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; SUPEROXIDE; THIOBARBITURIC ACID; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UREA;

ADRENAL DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; CARDITIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE EXACERBATION; ENZYME ACTIVITY; GLOMERULOSCLEROSIS; HEART DISEASE; HEART HYPERTROPHY; HEART INJURY; HEART MUSCLE FIBROSIS; INFLAMMATORY CELL; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY HYPERTROPHY; KIDNEY INJURY; LIPID PEROXIDATION; MALE; MYOFIBROBLAST; NEPHRITIS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN URINE LEVEL; RAT; UREA NITROGEN BLOOD LEVEL;

EID: 84867704482     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00257.2012     Document Type: Article

References (45)

1. Ammarguellat FZ, Gannon PO, Amiri F, Schiffrin EL. Fibrosis, matrix metalloproteinases, and inflammation in the heart of DOCA-salt hypertensive rats: role of ET(A) receptors. Hypertension 39: 679-684, 2002.
2. Beswick RA, Dorrance AM, Leite R, Webb RC. NADH/NADPH oxidase and enhanced superoxide production in the mineralocorticoid hypertensive rat. Hypertension 38: 1107-1111, 2001.
3. Beswick RA, Zhang H, Marable D, Catravas JD, Hill WD, Webb RC. Long-term antioxidant administration attenuates mineralocorticoid hypertension and renal inflammatory response. Hypertension 37: 781-786, 2001.
4. Callera GE, Touyz RM, Teixeira SA, Muscara MN, Carvalho MH, Fortes ZB, Nigro D, Schiffrin EL, Tostes RC. ETA receptor blockade decreases vascular superoxide generation in DOCA-salt hypertension. Hypertension 42: 811-817, 2003.
5. Callera GE, Tostes RC, Yogi A, Montezano AC, Touyz RM. Endothe-lin-1-induced oxidative stress in DOCA-salt hypertension involves NADPH-oxidase-independent mechanisms. Clin Sci (Lond) 110: 243-253, 2006.
6. Callera GE, Montezano AC, Touyz RM, Zorn TM, Carvalho MH, Fortes ZB, Nigro D, Schiffrin EL, Tostes RC. ETA receptor mediates altered leukocyte-endothelial cell interaction and adhesion molecules expression in DOCA-salt rats. Hypertension 43: 872-879, 2004.
7. Chao C, Madeddu P, Wang C, Liang Y, Chao L, Chao J. Differential regulation of kallikrein, kininogen, and kallikrein-binding protein in arterial hypertensive rats. Am J Physiol Renal Fluid Electrolyte Physiol 271: F78-F86, 1996.
8. Chao J, Yin H, Yao YY, Shen B, Smith RS Jr, Chao L. Novel role of kallistatin in protection against myocardial ischemia-reperfusion injury by preventing apoptosis and inflammation. Hum Gene Ther 17: 1201-1213, 2006.
9. Chen LM, Chao L, Chao J. Beneficial effects of kallikrein-binding protein in transgenic mice during endotoxic shock. Life Sci 60: 1431- 1435, 1997.
10. Chen VC, Chao L, Chao J. Reactive-site specificity of human kallistatin toward tissue kallikrein probed by site-directed mutagenesis. Biochim Biophys Acta 1479: 237-246, 2000.
11. Chen VC, Chao L, Pimenta DC, Bledsoe G, Juliano L, Chao J. Identification of a major heparin-binding site in kallistatin. J Biol Chem 276: 1276-1284, 2001.
12. Craven PA, Studer RK, Felder J, Phillips S, DeRubertis FR. Nitric oxide inhibition of transforming growth factor-beta and collagen synthesis in mesangial cells. Diabetes 46: 671-681, 1997.
13. Dobrzynski E, Wang C, Chao J, Chao L. Adrenomedullin gene delivery attenuates hypertension, cardiac remodeling, and renal injury in deoxycorticosterone acetate-salt hypertensive rats. Hypertension 36: 995-1001, 2000.
14. Eddy AA. Molecular basis of renal fibrosis. Pediatr Nephrol 15: 290-301, 2000.
15. Fenning A, Harrison G, Rose'Meyer R, Hoey A, Brown L. L-Arginine attenuates cardiovascular impairment in DOCA-salt hypertensive rats. Am J Physiol Heart Circ Physiol 289: H1408-H1416, 2005.
16. Gao L, Yin H, Smith RJ S, Chao L, Chao J. Role of kallistatin in prevention of cardiac remodeling after chronic myocardial infarction. Lab Invest 88: 1157-1166, 2008.
17. Gloire G, Legrand-Poels S, Piette J. NF-kB activation by reactive oxygen species: fifteen years later. Biochem Pharmacol 72: 1493-1505, 2006.
18. Jin L, Beswick RA, Yamamoto T, Palmer T, Taylor TA, Pollock JS, Pollock DM, Brands MW, Webb RC. Increased reactive oxygen species contributes to kidney injury in mineralocorticoid hypertensive rats. J Physiol Pharmacol 57: 343-357, 2006.
19. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 112: 1776-1784, 2003.
20. Kim S, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K, Inada Y, Wada T, Ishimura Y, Chatani F. Role of angiotensin II in renal injury of deoxycorticosterone acetate- salt hypertensive rats. Hypertension 24: 195-204, 1994.
21. Kirchhoff F, Krebs C, Abdulhag UN, Meyer-Schwesinger C, Maas R, Helmchen U, Hilgers KF, Wolf G, Stahl RA, Wenzel U. Rapid devel-opment of severe end-organ damage in C57BL/6 mice by combining DOCA salt and angiotensin II. Kidney Int 73: 643-650, 2008.
22. Komuro I. Molecular mechanism of cardiac hypertrophy and development. Jpn Circ J 65: 353-358, 2001.
23. Lariviere R, Day R, Schiffrin EL. Increased expression of endothelin-1 gene in blood vessels of deoxycorticosterone acetate-salt hypertensive rats. Hypertension 21: 916-920, 1993.
24. Leask A. Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ Res 106: 1675-1680, 2010.
25. Liu Y, Bledsoe G, Hagiwara M, Yang ZR, Shen B, Chao L, Chao J. Blockade of endogenous tissue kallikrein aggravates renal injury by enhancing oxidative stress and inhibiting matrix degradation. Am J Physiol Renal Physiol 298: F1033-F1040, 2010.
26. Ma JX, Chao L, Zhou G, Chao J. Expression and characterization of rat kallikrein-binding in Escherichia coli. Biochem J 292: 825-832, 1993.
27. Miao RQ, Murakami H, Song Q, Chao L, Chao J. Kallistatin stimulates vascular smooth muscle cell proliferation and migration in vitro and neointima formation in balloon-injured rat artery. Circ Res 86: 418-424, 2000.
28. Miao RQ, Agata J, Chao L, Chao J. Kallistatin is a new inhibitor of angiogenesis and tumor growth. Blood 100: 3245-3252, 2002.
29. Miao RQ, Chen V, Chao L, Chao J. Structural elements of kallistatin required for inhibition of angiogenesis. Am J Physiol Cell Physiol 284: C1604-C1613, 2003.
30. Paravicini TM, Touyz RM. NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities. Diabetes Care 31: S170-180, 2008.
31. Porter KE, Turner NA. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther 123: 255-278, 2009.
32. Rodriguez-Iturbe B, Vaziri ND, Herrera-Acosta J, Johnson RJ. Oxi-dative stress, renal infiltration of immune cells, and salt-sensitive hypertension: all for one and one for all. Am J Physiol Renal Physiol 286: F606-F616, 2004.
33. Rosenkranz S. TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res 63: 423-432, 2004.
34. Ruiz-Ortega M, Lorenzo O, Suzuki Y, Ruperez M, Egido J. Proin-flammatory actions of angiotensins. Curr Opin Nephrol Hypertens 10: 321-329, 2001.
35. Rush JW, Ford RJ. Nitric oxide, oxidative stress and vascular endothe-lium in health and hypertension. Clin Hemorheol Microcirc 37: 185-192, 2007.
36. Sharma K, Jin Y, Guo J, Ziyadeh FN. Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 45: 522-530, 1996.
37. Shen B, Hagiwara M, Yao YY, Chao L, Chao J. Salutary effect of kallistatin in salt-induced renal injury, inflammation, and fibrosis via antioxidative stress. Hypertension 51: 1358-1365, 2008.
38. Shen B, Chao L, Chao J. Pivotal role of JNK-dependent FOXO1 activation in downregulation of kallistatin expression by oxidative stress. Am J Physiol Heart Circ Physiol 298: H1048-H1054, 2010.
39. Shen B, Gao L, Hsu YT, Bledsoe G, Hagiwara M, Chao L, Chao J. Kallistatin attenuates endothelial apoptosis through inhibition of oxidative stress and activation of Akt-eNOS signaling. Am J Physiol Heart Circ Physiol 299: H1419-H1427, 2010.
40. Sorokin A, Kohan DE. Physiology and pathology of endothelin-1 in renal mesangium. Am J Physiol Renal Physiol 285: F579-F589, 2003.
41. Tsuchiya K, Naruse M, Nihei H. Glomerular expression of endothelial nitric oxide synthase in deoxycorticosterone acetate-salt-treated rats. Clin Exp Pharmacol Physiol 27: 818-820, 2000.
42. Wang CR, Chen SY, Wu CL, Liu MF, Jin YT, Chao L, Chao J. Prophylactic adenovirus-mediated human kallistatin gene therapy suppresses rat arthritis by inhibiting angiogenesis and inflammation. Arthritis Rheum 52: 1319-1324, 2005.
43. Xia CF, Bledsoe G, Chao L, Chao J. Kallikrein gene transfer reduces renal fibrosis, hypertrophy, and proliferation in DOCA-salt hypertensive rats. Am J Physiol Renal Physiol 289: F622-F631, 2005.
44. Yin H, Gao L, Shen B, Chao L, Chao J. Kallistatin inhibits vascular inflammation by antagonizing tumor necrosis factor-alpha-induced nuclear factor kappaB activation. Hypertension 56: 260-267, 2010.
45. Ying WZ, Sanders PW. The interrelationship between TGF-beta1 and nitric oxide is altered in salt-sensitive hypertension. Am J Physiol Renal Physiol 285: F902-F908, 2003.